Julian Lippert

Dr. Julian Lippert


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JLJulian Lippert
Julian Lippert
AGAdrian G. Guggisberg
Adrian G. Guggisberg
Severe traumatic brain injury (TBI) may cause disorders of consciousness (DoC) in the form of coma, unresponsive wakefulness syndrome (UWS), or minimally conscious state (MCS). Despite significant advancements made over the last two decades in detecting, predicting, and promoting the recovery of consciousness in TBI patients with DoC, the available diagnostic and treatment choices remain limited. In cases of severe TBI, the dissolution of consciousness both in the acute and post-acute phases constitutes one of the major clinical findings and challenges. In clinical settings, neurologists and neurorehabilitation specialists are called on to discern the level of consciousness in patients who are unable to communicate, and to project outcomes and recommend approaches to treatment. Standards of care are not available to guide clinical decision-making for this population, often leading to inconsistent, inaccurate, and inappropriate care. Recent studies refer to network-based mechanisms of consciousness as a more promising method to predict outcomes and functional recovery. A further goal is the modulation of neural networks underlying awareness and arousal as the main components of consciousness. This review centers on the difficulties in characterizing individuals experiencing post-traumatic DoC and on the recent advancements made in the identification and prognostication of consciousness recovery through the utilization of advanced neuroimaging and electrophysiological techniques as well as biomarkers. Moreover, we discuss new treatment approaches and summarize recent therapeutic recommendations.

1 March 2024 in Stroke
Verified
Journal Article
Open access
PDF file
XYXiaoli Yang
Xiaoli Yang
JLJulian Lippert
Julian Lippert
MDMartijn Dekkers
Martijn Dekkers
SBSébastien Baillieul
Sébastien Baillieul
SDSimone B. Duss
Simone B. Duss
Claudio L.A. BassettiClaudio L.A. Bassetti
Claudio L.A. Bassetti
BACKGROUND: Sleep-disordered breathing (SDB) and atrial fibrillation (AF) are highly prevalent in patients with stroke and are recognized as independent risk factors for stroke. Little is known about the impact of comorbid SDB and AF on long-term outcomes after stroke. METHODS: In this prospective cohort study, 353 patients with acute ischemic stroke or transient ischemic attacks were analyzed. Patients were screened for SDB by respiratory polygraphy during acute hospitalization. Screening for AF was performed using a 7-day ECG up to 3× in the first 6 months. Follow-up visits were scheduled at 1, 3, 12, 24, and 36 months poststroke. Cox regression models adjusted for various factors (age, sex, body mass index, hypertension, diabetes, dyslipidemia, and heart failure) were used to assess the impact of comorbid SDB and AF on subsequent death or cerebro-cardiovascular events. RESULTS: Among 353 patients (299 ischemic stroke and 54 transient ischemic attacks), median age, 67 (interquartile range, 57–74) years with 63% males. Moderate-to-severe SDB (apnea-hypopnea index score, ≥15/h) was present in 118 (33.4%) patients. Among the 56 (15.9%) patients with AF, 28 had comorbid moderate-to-severe SDB and AF. Over 36 months, there were 12 deaths and 67 recurrent cerebro-cardiovascular events. Patients with comorbid moderate-to-severe SDB and AF had a higher risk of subsequent death or cerebro-cardiovascular events compared with those with only moderate-to-severe SDB without AF (hazard ratio, 2.49 [95% CI, 1.18–5.24]) and to those without moderate-to-severe SDB or AF (hazard ratio, 2.25 [95% CI, 1.12–4.50]). However, no significant difference was found between the comorbid moderate-to-severe SDB and AF group and the group with only AF without moderate-to-severe SDB (hazard ratio, 1.64 [95% CI, 0.62–4.36]). CONCLUSIONS: Comorbid moderate-to-severe SDB and AF significantly increase the risk of long-term mortality or recurrent cerebro-cardiovascular events after acute ischemic stroke. Considering both conditions as cumulative and modifiable cerebro-cardiovascular risk factors is of interest for the management of acute stroke. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02559739.

1 March 2026 in European Stroke Journal
Verified
Journal Article
Open access
PDF file
LBLukas Boos
Lukas Boos
JKJosefin E Kaufmann
Josefin E Kaufmann
MSMirjam I Sauter
Mirjam I Sauter
Philippe A. LyrerPhilippe A. Lyrer
Philippe A. Lyrer
AZAnnaelle Zietz
Annaelle Zietz
SEStefan T Engelter
Stefan T Engelter
Introduction: Post-stroke fatigue (PSF) is common and impacts stroke rehabilitation. Dopaminergic treatment may have beneficial effects on PSF. This study investigated whether levodopa, compared with placebo, was associated with a lower frequency or severity of PSF during in-hospital rehabilitation. Patients and methods: Enhancement of Stroke Rehabilitation with Levodopa (ESTREL)-Fatigue was an exploratory analysis of secondary outcome data obtained in the multicentre, randomised, placebo-controlled ESTREL trial. Participants with acute stroke received levodopa 100 mg/carbidopa 25 mg or placebo 3 times daily for 39 days to enhance motor recovery. Participants who (i) reported fatigue at 5 weeks and who (ii) took at least 80% of the study medication were included in ESTREL-Fatigue. No adjustments for confounding were made. The primary endpoint was the presence of PSF at 5 weeks, defined as a T-score of ≥ 55 on the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue-Short-form-4a. As secondary endpoints, T-score cutoffs of ≥ 60 (moderate fatigue) and ≥ 70 (severe fatigue) were used. Binary logistic regression was used to compare PSF at 5 weeks between treatment groups. Results are presented as odds ratios (ORs) with 95% CI. Results: A total of 456 of 505 (90.3%) participants were included (levodopa/placebo 235/221, median age 73 years, 41% female). Post-stroke fatigue at 5 weeks was present in 63/235 (26.8%) levodopa-treated participants and in 65/221 (29.4%) placebo-treated participants (OR: 0.88; 95% CI, 0.58–1.32; risk ratio 0.91; risk difference − 2.6%). For cutoffs of ≥ 60 and ≥ 70, ORs were 0.78 (95% CI, 0.43–1.41) and 0.8 (95% CI, 0.25–2.44), respectively. A sensitivity analysis as per intention-to-treat with all 610 randomised ESTREL participants also showed no significant difference in fatigue presence between levodopa and placebo groups (OR: 0.95; 95% CI, 0.65–1.39) and a sensitivity analysis using a mixed-effects logistic regression showed no evidence of centre-related clustering. Conclusion: In ESTREL-Fatigue, levodopa, compared to placebo, was not associated with less PSF during in-hospital rehabilitation.

23 October 2026 in Stroke
Verified
Journal Article
Open access
XYXiaoli Yang
Xiaoli Yang
JLJulian Lippert
Julian Lippert
SBStefan Bauer-Gambelli
Stefan Bauer-Gambelli
CHChristian M. Horvath
Christian M. Horvath
TMThomas Meinel
Thomas Meinel
Claudio L.A. BassettiClaudio L.A. Bassetti
Claudio L.A. Bassetti
BACKGROUND: Sleep-disordered breathing (SDB) is common after ischemic stroke and has been associated with adverse outcomes, yet evidence from large stroke cohorts remains limited. We evaluated the association of SDB severity with all-cause mortality, major adverse cardio- and cerebrovascular events (MACCE), and 3-month functional outcome. METHODS: This retrospective cohort study included consecutive patients with ischemic stroke or transient ischemic attack admitted to Inselspital Bern between 2017 and 2021 who underwent in-hospital respiratory polygraphy. SDB severity was classified according to the apnea-hypopnea index as mild (5–<15 events/h), moderate (15–<30 events/h), or severe (≥30 events/h). Outcomes included all-cause mortality, first postindex MACCE, and modified Rankin Scale scores at 3 months. Multivariable Cox and logistic regression models adjusted for age, sex, body mass index, vascular risk factors, admission National Institutes of Health Stroke Scale, intravenous thrombolysis, and mechanical thrombectomy. RESULTS: Among 1083 patients (mean age, 66.0±14.5 years; 62.6% male), SDB (apnea-hypopnea index ≥5 events/h) was present in 819 patients (75.6%), including mild (29.8%), moderate (22.9%), and severe (22.9%). Median follow-up was 51.1 months (interquartile range, 39.1–67.8) for mortality and 47.7 months (interquartile range, 36.9–65.5) for first postindex MACCE; 178 deaths and 153 of 880 patients experienced a first postindex MACCE. Severe SDB was independently associated with increased all-cause mortality (adjusted hazard ratio, 1.73 [95% CI, 1.04–2.89]). Mild, moderate, and severe SDB were associated with first postindex MACCE (adjusted hazard ratio, 1.78 [95% CI, 1.03–3.06]; 2.20 [95% CI, 1.26–3.84]; and 2.16 [95% CI, 1.23–3.78], respectively; P for trend=0.009). Moderate and severe SDB were associated with unfavorable 3-month functional outcome (adjusted odds ratio, 1.74 [95% CI, 1.01–3.04] and 2.48 [95% CI, 1.45–4.31], respectively; P for trend <0.001). CONCLUSIONS: Severe SDB was independently associated with all-cause mortality, whereas SDB severity was associated with first postindex MACCE and unfavorable 3-month functional outcome. Acute-phase SDB assessment may improve prognostic risk stratification.

1 January 2026 in European Stroke Journal
Verified
Journal Article
Open access
MSMirjam I Sauter
Mirjam I Sauter
JKJosefin E Kaufmann
Josefin E Kaufmann
LBLukas Boos
Lukas Boos
AZAnnaelle Zietz
Annaelle Zietz
STSimon Trüssel
Simon Trüssel
SEStefan T Engelter
Stefan T Engelter
Introduction: Post-stroke depression (PSD) frequently occurs after acute stroke and negatively affects rehabilitation. Dopamine has beneficial effects on motivation and emotional stability. In stroke patients, low dopamine levels are linked to PSD. This study investigated whether levodopa treatment during in-hospital rehabilitation impacts PSD compared to placebo. Patients and methods: ESTREL-Depression was a pre-planned analysis of the multicenter, randomized, double-blind, placebo-controlled ESTREL trial. Participants with an acute ischemic or hemorrhagic stroke were randomly assigned to receive either levodopa/carbidopa (100/25 mg) or placebo three times daily for 39 days. All ESTREL participants with (1) information about the presence or absence of depression at three months and (2) who took at least 80% of the study medication were eligible for the study. Participants with a history of depression were excluded. For the primary outcome, the presence of PSD was defined as having a T-score of ≥55 in the Patient-Reported Outcomes Measurement Information System short-form depression-4a 3 months after randomization. Binary logistic regression was performed to assess the effect of levodopa on PSD. Results: The study included 407 ESTREL participants (median age 72, 60% male), 209 receiving levodopa, and 198 receiving placebo. At 3 months, the frequency and odds of PSD did not differ between the levodopa group (26%) and the placebo group (28%) (OR = 0.93, 95% CI, 0.60–1.43). Conclusion: In the ESTREL-Depression study, treatment with levodopa had no impact on the occurrence of PSD. Clinical Trial Registration: ClinicalTrials.gov: NCT03735901 (https://clinicaltrials.gov/study/NCT03735901).